A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2472-2481

  Eliahu, Shay ^a   Barr, Haim M ^b   Camden, Jean ^c   Weisman, Gary A ^c   Fischer, Bilha ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b BIOLINERX LTD   (Israel)

^c University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; DI (2 METHYLTHIO) ADENOSINE 5',5'' PHOSPHORYL 1,PHOSPHORYL 3,ALPHA,BETA METHYLENE TRIPHOSPHATE; DI (2 METHYLTHIO) ADENOSINE 5',5'' PHOSPHORYL 1,PHOSPHORYL 4,ALPHA,BETA METHYLENE TETRAPHOSPHATE; DI (2 METHYLTHIO) ADENOSINE 5',5'' PHOSPHORYL 1,PHOSPHORYL 4,BETA,GAMMA METHYLENE TETRAPHOSPHATE; FURA 2; GLIBENCLAMIDE; GLUCOSE; INSULIN; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y1 RECEPTOR STIMULATING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENZYME STABILITY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT;

ALKALINE PHOSPHATASE; ANIMALS; BLOOD GLUCOSE; CELL LINE, TUMOR; DINUCLEOSIDE PHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; HUMANS; INSULIN; MALE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2; SERUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949842456     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901621h     Document Type: Article

References (46)

1. Fischer, B.; Nahum, V. Dinucleoside poly(borano)phosphate derivatives and uses thereof. U.S. Patent 7, 368, 439, 2008.
2. Ashcroft, F.; Rorsman, P. Type 2 diabetes mellitus: not quite exciting enough? Hum. Mol. Genet. 2004, 13, R21-R31.
3. Stumvoll, M.; Goldstein, B. J.; van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365, 1333-1346.
4. UPDSU Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-853.
5. Ishida, H. Mechanism of action of antidiabetic sulfonylureas. Diabetes Front. 1999, 10, 99-104.
6. Lebovitz, H. Oral Antidiabetic Agents; Lea and Febiger: Philadelphia, 1994; pp 508-529.
7. Leibowitz, G.; Cerasi, E. Sulfonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing? Diabetologia 1996, 39, 503-514.
8. Coutinho-Silva, R.; Parsons, M.; Robson, T.; Burnstock, G. Changes in expression of P2 receptors in rat and mouse pancreas during development and ageing. Cell Tissue Res. 2001, 306, 373-383.
9. Farret, A.; Lugo-Garcia, L.; Galtier, F.; Gross, R.; Petit, P. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: Implications for the treatment of type 2 diabetes. Fundam. Clin. Pharmacol. 2005, 19, 641-656.
10. 2+ concentration in human pancreatic islets and insulinoma cells. FEBS Lett. 1991, 291, 310-314.
11. Leon, C.; Freund, M.; Latchoumanin, O.; Farret, A.; Petit, P.; Cazenave, J.-P.; Gachet, C. The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. Purinergic Signalling 2005, 1, 145-151.
12. Bertrand, G.; Chapai, J.; Loubatieres-Mariani, M. M.; Roye, M. Evidence for two different P2-purinoceptors on beta cell and pancreatic vascular bed. Br. J. Pharmacol. 1987, 91, 783-787.
13. Fernandez-Alvarez, J.; Hillaire-Buys, D.; Loubatieres-Mariani, M. M.; Gomis, R.; Petit, P. P2 receptor agonists stimulate insulin release from human pancreatic islets. Pancreas 2001, 22, 69-71.
14. Abracchio, M. P.; Williams, M. In Purinergic and Pyrimidinergic Signaling; Springer: Berlin, 2001; Vol.151, pp 377-391.
15. Farret, A.; Vignaud, M.; Dietz, S.; Vignon, J.; Petit, P.; Gross, R. P2Y purinergic potentiation of glucose-induced insulin secretion and pancreatic beta-cell metabolism. Diabetes 2004, 53, S63-S66.
16. Chapai, J.; Hillaire-Buys, D.; Bertrand, G.; Pujalte, D.; Petit, P.; Loubatieres-Mariani, M. M. Comparative effects of adenosine5′-triphosphate and related analogs on insulin secretion from the rat pancreas. Fundam. Clin. Pharmacol. 1997, 11, 537-545.
17. Hillaire-Buys, D.; Shahar, L.; Fischer, B.; Chulkin, A.; Linck, N.; Chapal, J.; Loubatieres-Mariani, M. M.; Petit, P. Pharmacological evaluation and chemical stability of 2-benzylthioether-5′-O-(1-thio-triphosphate)- adenosine, a new insulin secretogogue acting through P2Y receptors. Drug Dev. Res. 2001, 53, 33-43.
18. Fischer, B.; Chulkin, A.; Boyer, J. L.; Harden, K. T.; Gendron, F.-P.; Beaudoin, A. R.; Chapal, J.; Hillaire-Buys, D.; Petit, P. 2-Thioether 5′-O-(l-thiotriphosphate)adenosine derivatives as new insulin secretagogues acting through P2Y-receptors. J. Med. Chem. 1999, 42, 3636-3646.
19. Nahum, V.; Zuendorf, G.; Levesque, S. A.; Beaudoin, A. R.; Reiser, G.; Fischer, B. Adenosine 5′-O-(l-boranotriphosphate) derivatives as novel P2Y1 receptor agonists. J. Med. Chem. 2002, 45, 5384-5396.
20. Farret, A.; Filhol, R.; Linck, N.; Manteghetti, M.; Vignon, J.; Gross, R.; Petit, P. P2Y receptor mediated modulation of insulin release by a novel generation of 2-substituted-5′-O-(1-borano-triphosphate)-adenosine analogues. Pharm. Res. 2006, 23, 2665-261X.
21. Chevassus, H.; Roig, A.; Belloc, C.; Lajoix, A. D.; Broca, C.; Manteghetti, M.; Petit, P. P2Y receptor activation enhances insulin release from pancreatic beta-cells by triggering the cyclic AMP/ protein kinase A pathway. Naunyn-Schmiedeberg 's Arch. Pharmacol. 2002, 366, 464-469.
22. 1 receptor agonists. Eur. J. Med. Chem. 2009, 44, 1525-1536.
23. Hoyle, C. H. V.; Hilderman, R. H.; Pintor, J. J.; Schluter, H.; King, B. F. Diadenosine polyphosphates as extracellular signal molecules. Drug Dev. Res. 2001, 52, 260-1212
24. Pintor, J.; Peral, A.; Hoyle, C. H. V.; Redick, C.; Douglass, J.; Sims, I.; Yerxa, B. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. J. Pharmacol. Exp. Ther. 2002, 500, 291-297.
25. Mediero, A.; Peral, A.; Pintor, J. Dual roles of diadenosine polyphosphates in corneal epithelial cell migration. Invest. Ophthalmol. Vis. Sci. 2006, 47, 4500-4506.
26. Guzman-Aranguez, A.; Crooke, A.; Peral, A.; Hoyle, C. H. V.; Pintor, J. Dinucleoside polyphosphates in the eye: from physiology to therapeutics. Prog. Retinal Eye Res. 2007, 26, 674-687.
27. Shaver, S. R.; Rideout, J. L.; Pendergast, W.; Douglass, J. G.; Brown, E. G.; Boyer, J. L.; Patel, R. I.; Redick, C. C.; Jones, A. C.; Picher, M.; Yerxa, B. R. Structure-activity relationships of dinucleotides: potent and selective agonists of P2Y receptors. Purinergic Signalling 2005, 1, 183-191.
28. Yerxa, B. R.; Sabater, J. R.; Davis, C. W.; Stutts, M. J.; Lang-Furr, M.; Picher, M.; Jones, A. C.; Cowlen, M.; Dougherty, R.; Boyer, J.; Abraham, W. M.; Boucher, R. C. Pharmacology of INS37217 [P1-(uridine 5′)-P4-(2′- deoxycytidine 5′)tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 2002, 302, 871-880.
29. Guranowski, A.; Biryukov, A.; Tarussova, N. B.; Khomutov, R. M.; Jakubowski, H. Phosphonate analogs of diadenosine 5′,5'"-P1, P4-tetraphosphate as substrates or inhibitors of prokaryotic and eukaryotic enzymes degrading dinucleoside tetraphosphates. Biochemistry 1987, 26, 3425-3429.
30. Nahum, V.; Tulapurkar, M.; Levesque, S. A.; Sevigny, J.; Reiser, G.; Fischer, B. Diadenosine and diuridine poly(borano)phosphate analogs: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. J. Med. Chem. 2006, 49, 1980-1990.
31. Fischer, B.; Boyer, J. L.; Hoyle, C. H. V.; Ziganshin, A. U.; Brizzolara, A. L.; Knight, G. E.; Zimmet, J.; Burnstock, G.; Harden, T. K.; Jacobson, K. A. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J. Med. Chem. 1993, 36, 3937-3946.
32. Zatorski, A.; Goldstein, B. M.; Colby, T. D.; Jones, J. P.; Pankiewicz, K. W. Potent inhibitors of human inosine monophosphate dehydrogenase type II. fluorine-substituted analogs of thiazole-4-carboxamide adenine dinucleotide. J. Med. Chem. 1995, 38, 1098-1105.
33. Hoard, D. E.; Ott, D. G. Conversion of mono- and oligodeoxyribonucleotides to 5′-triphosphates. J. Am. Chem. Soc. 1965, 87, 1785-1788.
34. 2u nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3275-3279.
35. Ostergard, T.; Degn, K. B.; Gall, M.-A.; Carr, R. D.; Veldhuis, J. D.; Thomsen, M. K.; Rizza, R. A.; Schmitz, O. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. J. Clin. Endocrinol. Metab. 2004, 89, 297-302.
36. Hull, W. E.; Halford, S. E.; Gutfreund, H.; Sykes, B. D. Phosphorus-31 nuclear magnetic resonance study of alkaline phosphatase: the role of inorganic phosphate in limiting the enzyme turnover rate at alkaline pH. Biochemistry 1976, 15, 1547-1561.
37. Moss, D. W.; Walli, A. K. Intermediates in the hydrolysis of ATP by human alkaline phosphatase. Biochim. Biophys. Acta, Enzymol. 1969, 191, 416-1411
38. Harada, M.; Udagawa, N.; Fukasawa, K.; Hiraoka, B. Y.; Mogi, M. Inorganic pyrophosphatase activity of purified bovine pulp alkaline phosphatase at physiological pH. J. Dent. Res. 1986, 65, 125-127.
39. Grau, V. Union de diguanosin tetrafosfato a cerebro de rata. Universidad de Extremadura: Badajoz, Spain, 1982.
40. Luethje, J.; Ogilvie, A. Catabolism of Ap4A and Ap3A in whole blood. The dinucleotides are long-lived signal molecules in the blood ending up as intracellular ATP in the erythrocytes. Eur. J. Biochem. 1988, 173, 241-245.
41. Skoblov, M. Y.; Yas'ko, M. V.; Skoblov, Y. S. The preparation of 32P-labeled 2-methylthioadenosine di- and triphosphates. Bioorg. Khim. 1999, 25, 702-707.
42. Davisson,V. J.; Davis, D. R.; Dixit, V. M.; Poulter, C. D. Synthesis of nucleotide 5′-diphosphates from 5′-O-tosyl nucleosides. J. Org. Chem. 1987, 52, 1794-1801.
43. Boeynaems, J.-M.; Goldman, M.; Marteau, F.; Communi, D. Use of purinergic and pyrimidinergic receptor agonists for dendritic cell-based immunotherapies. Patent 2006-EP7966 2007020018, 20060811, 2007.
44. Brandenberger, H.; Hanson, R. Spectrophotometric determination of acid and alkaline phosphatases. Helv. Chim. Acta 1953, 36, 900-906.
45. 2 nucleotide receptor. Consequences of truncation of the C terminus. J. Biol. Chem. 1998, 273, 29437-29444.
46. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.